Abstract:Background Proteasome inhibitor bortezomib is an effective approach to the treatment of multiple myeloma (MM), but drug resistance often emerges and limits its retreatment. However, the action mechanisms are not fully understood. Several lines of evidence link E3 ligase to myeloma and its drug resistance. Pirh2 (p53-induced RING-H2) E3 ubiquitin ligase with intrinsic ubiquitin-protein ligase activity for polyubiquitination and subsequently proteasomal degradation was predisposed for plasma cell hyperplasia and tumorigenesis as reported. In this study, we examined Pirh2 expression in plasma cells of the bone marrow (CD138+ cells) from MM patients and investigate the effect of Pirh2 on the viability, proliferation, survival and drug resistance of MM cells. Methods Bortezomib-sensitive malignant haematopoetic cells can acquire secondary resistance to Bortezomib in vitro. To identify some of the mechanisms involved, we developed myeloma cell lines OPM-2 and RPMI8226 bortezomib resistant (OPM-2-BR, RPMI8226-BR) derivative lines by continuous culture in sub-lethal concentrations of bortezomib. Clones of OPM-2-BR and RPMI8226-BR were obtained after several months, and acquired resistance to bortezomib remained stable over months with extended stimulus duration in the presence of bortezomib. Pirh2 mRNA and protein expressions were detected by real time quantitative PCR(Q-RT PCR) and Western blotting. We also generated stable Pirh2 knock down cell lines and stable Pirh2 overexpression cell lines. Results We found differential expression of Pirh2 in bortezomib-resistant (BR) cells, compared to wild type (WT) controls by Q-RT PCR and Western blotting. We confirmed generally Pirh2 mRNA and protein expressions in MM cell lines. Besides, Pirh2 mRNA expression was also determined from bone marrow samples of MM patients. In summary, we showed that Pirh2 is more highly expressed in MM cell lines and patient MM cells (from newly diagnosed or refractory/recurrence patients with MM) than in normal bone marrow mononuclear cells from normal donors ( P ). Interestingly, We found that Pirh2 overexpression cell lines showed negatively effect on the response to bortezomib treatment. Consistent with this, Pirh2 knock down cell lines can overcome bortezomib resistance. Conclusions Collectively, Our findings demonstrate a novel role for Pirh2, which suggests that Pirh2 may act by an unknown mechanism involved in bortezomib resistance of MM. An improved understanding of it can lead to better therapeutics for bortezomib retreatment which will be a rational strategy for clinical translation. Disclosures No relevant conflicts of interest to declare.

Dysregulation of Unfolded Protein Response Partially Underlies Proapoptotic Activity of Bortezomib in Multiple Myeloma Cells

Bortezomib Therapeutic Effect is Associated with Expression of Fgfr3 in Multiple Myeloma Cells

Inhibition of Hsp90 by Triptolide (tpl) Augments Bortezomib-Induced U266 Cells Apoptosis

Down-Regulation of CD9 by Methylation Decreased Bortezomib Sensitivity in Multiple Myeloma

[Proteasome Inhibitor Induces Apoptosis and Influences the Expression of Notch1 and NF-kappaB in Multiple Myeloma RPMI8226 Cells].

Pirh2 mediates the sensitivity of myeloma cells to bortezomib via canonical NF-κB signaling pathway

Blockade of PLD1 Potentiates the Antitumor Effects of Bortezomib in Multiple Myeloma Cells by Inhibiting the Mtor/nf-Κb Signal Pathway

Proteasome inhibition induces apoptosis through simultaneous inactivation of MCL-1/BCL-XL by NOXA independent of CHOP and JNK pathways

Distinct pathway activities are associated with prognosis and response to bortezomib-containing treatment in MCL1-M based molecular subtypes of multiple myeloma

4-Chlorobenzoyl Berbamine, a Novel Berbamine Derivative, Induces Apoptosis in Multiple Myeloma Cells Through the IL-6 Signal Transduction Pathway and Increases FOXO3a-Bim Expression.

Blockade of HSP70 by VER-155008 Synergistically Enhances Bortezomib-Induced Cytotoxicity in Multiple Myeloma

Curcumin Enhances Bortezomib Treatment of Myeloma by Inhibiting Heat Shock Protein 90 Expression

Endoplasmic-reticulum stress pathway-associated mechanisms of action of proteasome inhibitors in multiple myeloma

HMGB1 Knockdown Increases MM Cell Vulnerability by Regulating Autophagy and DNA Damage Repair

Antitumor Activity and Drug Interactions of Proteasome Inhibitor Bortezomib in Human High-Risk Myelodysplastic Syndrome Cells.

Deubiquitylase USP12 induces pro-survival autophagy and bortezomib resistance in multiple myeloma by stabilizing HMGB1

Bortezomib Inhibits Multiple Myeloma Cells by Transactivating ATF3 to Trigger miR-135a-5p- Dependent Apoptosis

DKK1 Suppresses WWP2 to Enhance Bortezomib Resistance in Multiple Myeloma Via Regulating GLI2 Ubiquitination

MiR-34c-5p Inhibition Affects Bax/Bcl2 Expression and Reverses Bortezomib Resistance in Multiple Myeloma Cells

Bortezomib-Resistance is Characterized by Upregulation of E3 Ligase Pirh2 Which Protects Bortezomib Induced Apoptosis in Multiple Myeloma Cells